Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I The "Reading the Mind in the Eyes" Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry. 2001 Feb;42(2):241-51.
Combs DR, Penn DL, Wicher M, Waldheter E The Ambiguous Intentions Hostility Questionnaire (AIHQ): a new measure for evaluating hostile social-cognitive biases in paranoia. Cogn Neuropsychiatry. 2007 Mar;12(2):128-43.
Liebowitz MR Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141-73.
Pinkham AE, Penn DL Neurocognitive and social cognitive predictors of interpersonal skill in schizophrenia. Psychiatry Res. 2006 Aug 30;143(2-3):167-78. Epub 2006 Jul 21.
Randolph C, Tierney MC, Mohr E, Chase TN The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998 Jun;20(3):310-9.
Schneider LC, Struening EL SLOF: a behavioral rating scale for assessing the mentally ill. Soc Work Res Abstr. 1983 Fall;19(3):9-21.
Williams KD, Cheung CK, Choi W Cyberostracism: effects of being ignored over the Internet. J Pers Soc Psychol. 2000 Nov;79(5):748-62.
Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
